ArticleBrain, behavior, & immunity - health2025
Characterization of inflammatory and neurofunctional markers in the context of early life stress among a clinical sample of people maintained on buprenorphine for opioid use disorder.
Article in Brain, behavior, & immunity - health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early life stress (ELS) is associated with an increase in expression of inflammatory cytokines and opioid addiction-related behaviors. Maintenance on medication for opioid use disorder (OUD) can opposingly affect these endpoints. The study aimed to determine whether a history of ELS is associated with a distinct inflammatory and/or neurofunctional phenotype within a population of individuals maintained on buprenorphine for OUD. In this secondary analysis of 21 adults (16M/5F), High and Low ELS groups were determined by number of items endorsed on the Trauma History Questionnaire occurring before 18 years old. Peripheral blood levels of 10 cytokines, CRP, LBP, and MCP-1 were assessed. Participants also completed assessments of six neurofunctional domains: reward, cognition, negative emotionality, interoception, metacognition, and sleep. Individuals in the Low ELS group (n = 11; 9M/2F) experienced a median of 3 [range: 0-3] traumatic events and individuals in the High ELS group (n = 10; 7M/3F) experienced a median of 8.5 [4-13] traumatic events. ELS groups did not differ with respect to age, sex, buprenorphine dose, BMI, smoking status, psychiatric or substance use disorder comorbidity. Proinflammatory cytokines IFNγ (p < 0.001) and IL-6 (p < 0.0001) were elevated in the High ELS group compared to the Low ELS group. Anti-inflammatory IL-13 was higher in the Low ELS group (p = 0.012). There were no neurofunctional differences between ELS groups. Results extend previous findings of an ELS-associated pro-inflammatory state to this OUD treatment population. Future work with larger samples balanced by sex may inform precision medicine strategies to tailor buprenorphine-based OUD treatment to individuals' biopsychosocial needs.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.